Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Supplemental material
  • Version history
  • Article usage
  • Citations to this article

Advertisement

ResearchIn-Press PreviewHepatologyInflammationMetabolism Open Access | 10.1172/JCI191074

ER stress upregulates S100A11 in steatohepatitis models via epigenetic modifications within the lipotoxicity influenced enhancer

P. Vineeth Daniel,1 Hanna L. Erickson,1 Daheui Choi,2 Feda H. Hamdan,1 Yasuhiko Nakao,1 Gyanendra Puri,1 Takahito Nishihara,1 Yeriel Yoon,1 Amy S. Mauer,1 Debanjali Dasgupta,1 Jill Thompson,3 Alexander Revzin,2 and Harmeet Malhi1

1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, United States of America

2Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, United States of America

3Department of Molecular Medicine, Mayo Clinic, Rochester, United States of America

Find articles by Daniel, P. in: PubMed | Google Scholar |

1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, United States of America

2Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, United States of America

3Department of Molecular Medicine, Mayo Clinic, Rochester, United States of America

Find articles by Erickson, H. in: PubMed | Google Scholar

1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, United States of America

2Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, United States of America

3Department of Molecular Medicine, Mayo Clinic, Rochester, United States of America

Find articles by Choi, D. in: PubMed | Google Scholar

1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, United States of America

2Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, United States of America

3Department of Molecular Medicine, Mayo Clinic, Rochester, United States of America

Find articles by Hamdan, F. in: PubMed | Google Scholar

1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, United States of America

2Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, United States of America

3Department of Molecular Medicine, Mayo Clinic, Rochester, United States of America

Find articles by Nakao, Y. in: PubMed | Google Scholar

1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, United States of America

2Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, United States of America

3Department of Molecular Medicine, Mayo Clinic, Rochester, United States of America

Find articles by Puri, G. in: PubMed | Google Scholar

1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, United States of America

2Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, United States of America

3Department of Molecular Medicine, Mayo Clinic, Rochester, United States of America

Find articles by Nishihara, T. in: PubMed | Google Scholar

1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, United States of America

2Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, United States of America

3Department of Molecular Medicine, Mayo Clinic, Rochester, United States of America

Find articles by Yoon, Y. in: PubMed | Google Scholar

1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, United States of America

2Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, United States of America

3Department of Molecular Medicine, Mayo Clinic, Rochester, United States of America

Find articles by Mauer, A. in: PubMed | Google Scholar

1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, United States of America

2Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, United States of America

3Department of Molecular Medicine, Mayo Clinic, Rochester, United States of America

Find articles by Dasgupta, D. in: PubMed | Google Scholar

1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, United States of America

2Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, United States of America

3Department of Molecular Medicine, Mayo Clinic, Rochester, United States of America

Find articles by Thompson, J. in: PubMed | Google Scholar

1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, United States of America

2Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, United States of America

3Department of Molecular Medicine, Mayo Clinic, Rochester, United States of America

Find articles by Revzin, A. in: PubMed | Google Scholar

1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, United States of America

2Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, United States of America

3Department of Molecular Medicine, Mayo Clinic, Rochester, United States of America

Find articles by Malhi, H. in: PubMed | Google Scholar |

Published September 30, 2025 - More info

J Clin Invest. https://doi.org/10.1172/JCI191074.
Copyright © 2025, Daniel et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published September 30, 2025 - Version history
View PDF
Abstract

Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease characterized by complex interactions between lipotoxicity, ER stress responses, and immune-mediated inflammation. We identified enrichment of the proinflammatory alarmin S100 calcium-binding protein A11 (S100A11) on extracellular vesicles stimulated by palmitate-induced lipotoxic ER stress with concomitant upregulation of hepatocellular S100A11 abundance in an IRE1A-XBP1s dependent manner. We next investigated the epigenetic mechanisms that regulate this stress response. Publicly available human liver ChIP-Seq GEO datasets demonstrated a region of histone H3 lysine 27 (H3K27) acetylation upstream to the S100A11 promoter. H3K27acetylation ChIP-qPCR demonstrated a positive correlation between lipotoxic ER stress and H3K27acetylation of the region, which we termed Lipotoxicity Influenced Enhancer (LIE) domain. CRISPR-mediated repression of the LIE domain reduced palmitate-induced H3K27acetylation and corresponding S100A11 upregulation in Huh7 cells and immortalized mouse hepatocytes. Silencing of the murine LIE in two independent steatohepatitis models demonstrated reduced S100a11 upregulation and attenuated liver injury. We confirmed H3K27acetylation and XBP1s occupancy at the LIE domain in human MASH liver samples and an increase in hepatocyte-derived S100A11-enriched extracellular vesicles in MASH patient plasma. Our studies demonstrate a LIE domain which mediates hepatic S100A11 upregulation. This pathway may be a potential therapeutic target in MASH.

Supplemental material

View Unedited blot and gel images

View

Version history
  • Version 1 (September 30, 2025): In-Press Preview

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Supplemental material
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts